Leading Innovation
in Genetically-designed
Vaccines

News update!

BioNet’s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA)

“Monovalent recombinant acellular pertussis vaccine proven to significantly boost immunity against pertussis”

Sottomesso all’Agenzia Europea per i Medicinali (EMA) il dossier del vaccino ricombinante antipertosse di BioNet

“Il vaccino acellulare antipertosse monovalente ricombinante ha dimostrato di migliorare significativamente l’immunità contro la pertosse”

Le vaccin recombinant contre la coqueluche de BioNet soumis à l’Agence européenne des médicaments (EMA)

« Le vaccin coquelucheux recombinant non-combiné acellulaire démontré comme renforçant considérablement l’immunité contre la coqueluche »

Sharing Vaccine Expertise

BioNet is a biotech company focusing on bio-innovation and access to genetically-designed vaccines with business and clinical operations in North America, Europe, Australia and with a manufacturing base in Asia.

Our 200 collaborators across the globe are fully dedicated to the development, manufacturing and supply of vaccines against re-emerging and pandemic diseases.

Latest Publications

Transplacental transfer of maternal antibodies following immunization with recombinant pertussis vaccines during pregnancy: Real-world evidence

Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines

Pertussis Updates and Insights

Alliance Network for Global Vaccine Access

“Sharing vaccine expertise”, our commitment to accelerating vaccine development and access is evident through our innovative bio-clusters and strategic manufacturing alliances. By collaborating with universities, research institutes, international organizations, biotech start-ups, and leading vaccine manufacturers, we drive cutting-edge advancements and ensure efficient global vaccine distribution.